In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Type

Guidance programme 6 selected

Guidance programme

Showing 1 to 5 of 5

TitleConsultationTypeConsultation end date
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]Draft guidanceTechnology appraisal guidance
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]Draft guidanceTechnology appraisal guidance
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Draft guidanceTechnology appraisal guidance
Nemolizumab for treating prurigo nodularis [ID6451]Draft guidanceTechnology appraisal guidance
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]Draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All